Liraglutide
From PeptideSciences101, the open peptide reference. · Last updated: May 31, 2026
This article is a stub. A peer-reviewed deep-dive is in preparation. Help contribute to expand it.
…
Overview
Daily injectable GLP-1 agonist sold as Victoza and Saxenda.
Reported benefits
Weight loss, blood sugar control, cardiovascular protection
Protocols & dosing
Typical dosage: 0.6-3.0 mg (daily).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
Liraglutide is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.
| Country | Status |
|---|---|
| United States | FDA approved |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Nausea, GI disturbances, potential pancreatitis
References
No external sources have been catalogued for this article yet.
Related peptides
- AOD-9604 — Fat loss, metabolic enhancement
- CagriSema — Combination therapy
- Dulaglutide — Weekly GLP-1 (Trulicity)
- Fragment 176-191 — HGH fragment for fat loss
- Leptin — Satiety hormone
- MOTS-c — Mitochondrial optimization
Categories: Weight Management & Metabolic